DaVita Inc (DVA)

Nov 3, 2026

U.S. Physical Therapy (USPH) is scheduled to report earnings this Wednesday after market close. Analysts expect revenue to grow by 8.7% year-on-year, a slowdown from the 17.3% growth in the same quarter last year. The company has a history of rarely missing Wall Street's revenue estimates, and investor sentiment in the healthcare providers & services segment has been positive recently.

Nov 1, 2026

Valero Energy Corporation is acquiring LyondellBasell's former Houston Refinery site for $320.5 million and plans to restart 165,000 barrels per day of processing capacity by the end of 2027. This strategic acquisition expands Valero's Gulf Coast refining footprint amidst strong refining margins and aligns with broader U.S. administration efforts to boost domestic fuel capacity. The deal is expected to be accretive for Valero shareholders, providing low-cost capacity, while offering longer-term benefits for consumers through increased fuel supply.

Oct 31, 2026

Berkshire Hathaway shares reached new all-time highs despite a lackluster week, with Class A stock closing at a record $821,931 and Class B shares setting a new intraday record. The company's stock benefited from a "back-to-basics" rotation as money moved away from AI and tech stocks, resulting in an 8.9% gain for October. However, Berkshire's significant stake in Alphabet took a hit due to disappointing earnings and concerns about AI infrastructure costs, causing its value to drop by a quarter.

Oct 30, 2026

DaVita Inc. reported strong third-quarter 2026 results, with adjusted EPS of $3.82 and revenues of $3.58 billion, both surpassing analyst estimates. The growth was primarily driven by robust performance in Integrated Kidney Care (IKC) and international operations, alongside an increase in U.S. dialysis treatments. The company also narrowed its adjusted operating income and EPS guidance for 2026 while raising its IKC-adjusted operating income expectations.

Oct 29, 2026

DaVita Inc. reported a Q3 adjusted operating income of $561 million and adjusted EPS of $3.82, narrowing full-year guidance for adjusted operating income to $2.175 billion to $2.25 billion. The company is nationally rolling out Expanded HD dialyzers, anticipating significant patient care improvements and mortality rate reductions, with financial benefits expected in late 2028. Integrated Kidney Care performed well, increasing its adjusted operating income guidance to at least $65 million for 2026, supported by a new Humana partnership and improved savings rates.

Oct 29, 2026

Shares of DaVita Inc. (DVA) advanced 5.10% to $193.31 on Thursday, outperforming the broader stock market, which saw the S&P 500 Index and Dow Jones Industrial Average decline. This marks the second consecutive day of gains for DaVita's stock.

Oct 29, 2026

DaVita Inc. (NYSE: DVA) reported Q3 2026 results that exceeded revenue and non-GAAP profit expectations, with revenue up 4.6% year-on-year to $3.58 billion and adjusted EPS of $3.82. Despite beating estimates and slightly raising full-year EPS guidance, the stock dropped 6.2% to $181.26 immediately after the announcement, indicating the market may have hoped for more significant positive news. The company demonstrated sustained profitability and share count reduction, boosting EPS growth.

Oct 29, 2026

WorldBlu has announced its 2026 List of Certified Freedom-Centered Organizations, recognizing DaVita, Grupo Elektra, and other organizations across six countries for their commitment to organizational democracy. This 20th annual award highlights companies that prioritize democratic leadership and design, enabling employees to self-manage and make decisions rather than relying on excessive hierarchy. WorldBlu's research suggests that these certified organizations have historically shown significantly higher cumulative revenue growth compared to S&P 500 companies.

Oct 28, 2026

DaVita Inc. (NYSE:DVA) is set to report earnings this Thursday. The company beat revenue expectations last quarter but missed full-year EPS guidance. Analysts generally anticipate revenue growth of 2.8% year-on-year for the upcoming quarter, and the stock is trading below its average analyst price target.

Oct 28, 2026

Shares of DaVita Inc. (DVA) rose 1.23% to $183.93 on a favorable trading day, outperforming the broader market indexes like the S&P 500 and Dow Jones Industrial Average. The company's stock closed 25.68% below its 52-week high reached in August.

Oct 28, 2026

The U.S. Attorney’s Office for the Eastern District of Kentucky has reached an ADA settlement with DaVita, Inc. concerning a deaf patient in Lexington. The agreement addresses allegations that DaVita failed to provide an American Sign Language (ASL) interpreter for the patient, which prevented effective communication during dialysis treatments. As part of the settlement, DaVita will update its policies, train staff, report future complaints, and pay $125,000 to the complainant and a $50,000 penalty.

Oct 27, 2026

DaVita (DVA) stock saw a significant rise of 71.6% from January to October 2026, driven by higher profit forecasts in its February and May quarterly reports. However, the gains were partly offset after its August report, which indicated a decrease in revenue per treatment due to patients leaving Obamacare plans. Despite the stock's volatility, the company's net income and operating margin remained relatively flat, with per-share profit growth primarily attributable to share buybacks and a reduced share count rather than substantial operational improvements.